AR006640A1 - Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido - Google Patents

Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido

Info

Publication number
AR006640A1
AR006640A1 ARP970101488A ARP970101488A AR006640A1 AR 006640 A1 AR006640 A1 AR 006640A1 AR P970101488 A ARP970101488 A AR P970101488A AR P970101488 A ARP970101488 A AR P970101488A AR 006640 A1 AR006640 A1 AR 006640A1
Authority
AR
Argentina
Prior art keywords
hydrogen
alkyl
substituted
halogen
alkoxy
Prior art date
Application number
ARP970101488A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20402358&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR006640(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR006640A1 publication Critical patent/AR006640A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un procedimiento para la preparación de una sal de magnesio de un compuesto heterociclico sulfinilo-substituido que contiene una porción imidazoltal como en los compuestos de la fórmula (I) donde Ar es (II); Z es (III) y X es (IV), donde N en elinterior del anillo benceno de la porción bencimidazolsignifica que uno de los átomos substituídos con R7, R10 puede estar opcionalmente intercambiado con un átomo de nitrógeno sin ningún substituyente:R1, R2 y R3 son iguales o dif erentes y estánseleccionados entre hidrógeno, alquilo, alcoxi opcionalmente substituido con fluor, alcoxialcoxi dialquilaminopiperidina, morfolino, halógeno, fenilalquilo y fenilalcoxi; R4 y R5 son iguales o diferentes y están seleccionad os entre hidrógeno,alquilo y aralquiloR6 es hidrógeno, halógeno, trifluormetilo, alquilo y alcoxi; R7-R10 son iguales o diferentes y están seleccionados entre hidrógeno, alquilo, alcoxi, halógeno,haloalcoxi, alquilcaarbonilo, alcoxicarbonilo, oxaxol ilo,trifluoralquilo o grupos adyacentes R7-R10 para formar estructuras de anillo que pueden estaradicionalmente substituidas: R11 es hidrógeno o forma una cadena alquileno conjuntamente con R3 y R12 y R13 son iguales o diferentes y están seleccionadosentre hidrógeno, halógeno o alquilo o los grupos alquilo, grupos alcoxi y porciones de los mismos pueden ser de cadena recta o ramificada C2-C9 o puedencomprender grupos alquilo ciclicos, por ejemplo cicloalquilalquilo donde elheterociclo sulfinilo substituído de fórmula (I) se mezcla conjuntamente conuna base débil y una fuente de magnesio. Las sales preparadas por este procedimiento y las composiciones farmacéuticas que las contienen son útilescomo inhibidores de labomba de protones.
ARP970101488A 1996-04-26 1997-04-14 Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido AR006640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601598A SE508669C2 (sv) 1996-04-26 1996-04-26 Nytt förfarande

Publications (1)

Publication Number Publication Date
AR006640A1 true AR006640A1 (es) 1999-09-08

Family

ID=20402358

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101488A AR006640A1 (es) 1996-04-26 1997-04-14 Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido

Country Status (40)

Country Link
US (1) US6124464A (es)
EP (1) EP0897386B1 (es)
JP (1) JP4233115B2 (es)
KR (1) KR100468331B1 (es)
CN (1) CN1100776C (es)
AR (1) AR006640A1 (es)
AT (1) ATE222904T1 (es)
BR (1) BR9708829A (es)
CA (1) CA2251636C (es)
CZ (1) CZ295067B6 (es)
DE (1) DE69714987T2 (es)
DK (1) DK0897386T3 (es)
DZ (1) DZ2209A1 (es)
EE (1) EE03485B1 (es)
EG (1) EG23874A (es)
ES (1) ES2180981T3 (es)
HK (1) HK1016978A1 (es)
HR (1) HRP970210B1 (es)
HU (1) HUP9901798A3 (es)
ID (1) ID16685A (es)
IL (1) IL126716A (es)
IS (1) IS1984B (es)
MA (1) MA24143A1 (es)
MY (1) MY119011A (es)
NO (1) NO318850B1 (es)
NZ (1) NZ332154A (es)
PL (1) PL188824B1 (es)
PT (1) PT897386E (es)
RS (1) RS49718B (es)
RU (1) RU2163238C2 (es)
SA (1) SA97170759B1 (es)
SE (1) SE508669C2 (es)
SI (1) SI0897386T1 (es)
SK (1) SK282752B6 (es)
TN (1) TNSN97068A1 (es)
TR (1) TR199802156T2 (es)
TW (1) TW420676B (es)
UA (1) UA51699C2 (es)
WO (1) WO1997041114A1 (es)
ZA (1) ZA973153B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
PT1131316E (pt) * 1998-11-18 2004-10-29 Astrazeneca Ab Processo quimico e formulacao farmaceutica melhorados
CA2290893C (en) 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
DE60314105T2 (de) * 2002-03-05 2008-01-24 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
DE10234617B4 (de) * 2002-07-29 2013-04-04 Nycomed Gmbh Neues Salz von (S)-Pantoprazol
AU2003278406A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US20060247277A1 (en) * 2003-02-28 2006-11-02 Yatendra Kumar Polymorphs of s-omeprazole
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
ITMI20031813A1 (it) * 2003-09-23 2005-03-24 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di pantoprazolo e suoi sali.
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
WO2007146341A2 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of pantoprazole magnesium salt
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
JP2010519284A (ja) 2007-02-21 2010-06-03 シプラ・リミテッド エソメプラゾールマグネシウム二水和物の調製方法
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
EP2426111A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
CN106397399A (zh) * 2015-07-29 2017-02-15 陕西合成药业股份有限公司 一种泮托拉唑镁的精制方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
FI861772A (fi) * 1985-05-07 1986-11-08 Chemie Linz Ag Nya tieno(2,3-d)imidazolderivat och foerfarande for deras framstaellning.
FI864138A (fi) * 1985-10-16 1987-04-17 Fisons Plc Heterocykliska blandningar.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
CN1138534C (zh) * 1994-07-08 2004-02-18 阿斯特拉曾尼卡有限公司 多单元片剂

Also Published As

Publication number Publication date
ID16685A (id) 1997-10-30
CN1100776C (zh) 2003-02-05
DZ2209A1 (fr) 2002-12-03
IL126716A0 (en) 1999-08-17
IS1984B (is) 2005-02-15
EP0897386A1 (en) 1999-02-24
PL188824B1 (pl) 2005-04-29
NO318850B1 (no) 2005-05-18
MA24143A1 (fr) 1997-12-31
DE69714987D1 (de) 2002-10-02
BR9708829A (pt) 1999-08-03
HUP9901798A2 (hu) 2000-04-28
ZA973153B (en) 1997-10-27
CZ339898A3 (cs) 1999-03-17
SE508669C2 (sv) 1998-10-26
CA2251636A1 (en) 1997-11-06
NZ332154A (en) 2002-03-01
WO1997041114A1 (en) 1997-11-06
NO984903D0 (no) 1998-10-21
KR20000065018A (ko) 2000-11-06
SA97170759B1 (ar) 2006-09-25
EE9800363A (et) 1999-04-15
RU2163238C2 (ru) 2001-02-20
CA2251636C (en) 2001-04-10
RS49718B (sr) 2007-12-31
SE9601598L (sv) 1997-10-27
PL329683A1 (en) 1999-04-12
UA51699C2 (uk) 2002-12-16
SK282752B6 (sk) 2002-12-03
HRP970210B1 (en) 2002-06-30
JP2000509067A (ja) 2000-07-18
IL126716A (en) 2003-10-31
ATE222904T1 (de) 2002-09-15
EE03485B1 (et) 2001-08-15
ES2180981T3 (es) 2003-02-16
CN1216989A (zh) 1999-05-19
CZ295067B6 (cs) 2005-05-18
AU711345B2 (en) 1999-10-14
MY119011A (en) 2005-03-31
DK0897386T3 (da) 2002-10-28
SK140798A3 (en) 1999-04-13
SE9601598D0 (sv) 1996-04-26
TW420676B (en) 2001-02-01
DE69714987T2 (de) 2003-04-30
TR199802156T2 (xx) 1999-02-22
YU44898A (sh) 1999-07-28
JP4233115B2 (ja) 2009-03-04
HK1016978A1 (en) 1999-11-12
SI0897386T1 (en) 2002-12-31
AU2719397A (en) 1997-11-19
IS4872A (is) 1998-10-19
EG23874A (en) 2007-11-27
KR100468331B1 (ko) 2005-03-16
US6124464A (en) 2000-09-26
EP0897386B1 (en) 2002-08-28
PT897386E (pt) 2002-12-31
HUP9901798A3 (en) 2003-02-28
NO984903L (no) 1998-10-21
HRP970210A2 (en) 1998-04-30
TNSN97068A1 (fr) 1999-12-31

Similar Documents

Publication Publication Date Title
AR006640A1 (es) Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido
AR050267A1 (es) Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
ES2162466T3 (es) Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
AR005277A1 (es) Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos.
AR050181A1 (es) Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa
RU98121016A (ru) Способ получения магниевой соли замещенного сульфинил-гетероцикла
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
AR052559A1 (es) Derivados de pirazol para inhibir cdk's y gsk's
AR055057A1 (es) Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria.
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
BR9915895A (pt) Composto, uso do mesmo, processo para prepará-lo, método para o tratamento de um mamìfero, incluindo o homem, de condições resultantes de nìveis de circulação elevados de apob-100, e, composição farmacêutica
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
YU160189A (sh) Anelirani derivati tetrahidropiridinocetne kisline in postopki za njihovo pripravo
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
ES2039242T3 (es) Un procedimiento para la preparacion de nuevos derivados de piperidina.
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR034309A1 (es) Derivados fenilsulfonilaminofenilamina, procedimiento para su preparacion, medicamentos y el uso de dichos derivados para la preparacion de medicamentos antivirales
CO4940477A1 (es) Inhibidores de proteasa
AR061185A1 (es) Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
CO4810374A1 (es) Nueva utilizacion de compuestos para actividad anti- pruritica
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR035230A1 (es) Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
AR050154A1 (es) Derivados de acido butanoico, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden

Legal Events

Date Code Title Description
FG Grant, registration